Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE: PFE) raised its full-year 2026 financial guidance after reporting third-quarter revenue of $16.6 billion, relatively flat year over year. Revenue excluding Comirnaty and Paxlovid grew 7% excluding currency effects, while launched and acquired products grew 32% on that basis. Reported diluted earnings per share fell 9% to $0.56; adjusted diluted earnings per share remained $0.87.
Pfizer now expects 2026 revenue of $62.0–$64.0 billion, versus $60.5–$62.5 billion previously, and adjusted diluted earnings per share of $2.95–$3.05, versus $2.80–$3.00. Guidance includes a $650 million Innovent licensing charge with an unfavorable impact of approximately $0.10 per share. Growth in Eliquis and Padcev contrasted with declines in COVID-19 products and Prevnar. The Phase 3 MagnetisMM-32 study of Elrexfio met its primary endpoint of survival without disease progression.
Pfizer (PFE) appointed Cecile Guegan Chief Financial Officer and Executive Vice President, effective November 1, 2026, following unanimous board approval. She had served as interim Chief Financial Officer since August 16, 2026, overseeing financial operations, execution and strategic planning.
Guegan will oversee corporate finance, including audit, treasury, investor relations, tax, insurance, operations planning and analysis, corporate controllership, and business finance and analytics. She said her focus remains disciplined capital allocation and targeted investments intended to drive revenue growth later in the decade and beyond. Before becoming interim finance chief, she was responsible for financial operations and reporting across Pfizer’s biopharmaceutical business, covering all therapeutic areas and geographies. She has more than 25 years of pharmaceutical finance experience.
Pfizer (NYSE: PFE) announced that ELREXFIO met the primary endpoint in the Phase 3 MagnetisMM-32 trial in relapsed or refractory multiple myeloma. At a pre-specified interim analysis, the treatment significantly reduced the risk of disease progression or death versus investigator-selected standard regimens. The trial enrolled 523 adults previously treated with anti-CD38 therapy and lenalidomide.
Median progression-free survival, the time without disease progression or death, was not yet reached; estimated progression-free survival at 18 months was 68%. Overall survival data remain immature. Grade 3 or higher infections occurred in 27.5% of ELREXFIO patients versus 18.1% with comparator regimens; Grade 5 infections occurred in 0.8% versus 1.6%. No new safety signals were identified. Pfizer plans to submit the data to global health authorities and share detailed results at a future medical meeting and for publication.
Pfizer (PFE) received expanded FDA approval for TALZENNA plus XTANDI in an earlier setting for HRR-mutated metastatic prostate cancer. The combination is now approved for men with metastatic hormone-sensitive disease, including BRCA and non-BRCA mutations, detected by an FDA-authorized test.
In the Phase 3 TALAPRO-3 trial, treatment reduced the risk of progression on imaging or death by an estimated 52% versus placebo plus XTANDI. An estimated 77% of patients remained progression-free at three years. Grade 3 or higher anemia occurred in 51% of the combination group versus 3% of controls; 5% discontinued TALZENNA because of anemia. No new safety signals were identified.
An application for the expanded indication is under review by the European Medicines Agency. Pfizer plans or has begun additional global regulatory filings.
Pfizer (NYSE: PFE) reported Phase 2 infant data showing immune responses across all serotypes in its investigational 25-valent pneumococcal vaccine. The four-dose candidate, PF-07872412, showed safety and tolerability comparable to PREVNAR 20, with no related serious adverse events identified. Serotype 3 antibody concentrations were 8.8-fold higher one month after Dose 3 and approximately 15-fold higher one month after Dose 4 than with PREVNAR 20.
Three Phase 3 pediatric studies began earlier in 2026, involving up to 6,830 participants; enrollment is complete in a separate Phase 3 manufacturing-lot consistency study. Pfizer plans to bring a 35-valent adult candidate into clinical development by the end of 2026, pending regulatory alignment. If successful, Pfizer says the pediatric candidate could protect against serotypes responsible for approximately 84% of U.S. invasive pneumococcal disease cases in children under five.
Pfizer (PFE) will present infectious-disease research at IDWeek 2026 in Washington, D.C., from October 21–24, covering vaccines and anti-infective therapies. The program includes 57 abstracts. Highlights include Phase 2 infant data comparing its 25-valent pneumococcal vaccine candidate with PREVNAR 20, informing an ongoing pediatric Phase 3 program.
Phase 3 presentations cover the LP.8.1-adapted COMIRNATY vaccine in at-risk children aged 5–11 and the LB6V Lyme disease vaccine candidate in participants aged 5 and older. The European Medicines Agency began reviewing LB6V’s marketing application in August 2026. Pfizer says the Lyme findings support potential antibody-associated protection. Real-world studies examine ABRYSVO effectiveness across three seasons in nursing home residents and against RSV-associated hospitalization in Australian infants following maternal vaccination. PREVNAR 20 analyses show reductions in invasive pneumococcal disease and all-cause pneumonia among U.S. adults aged 65 and older.
Pfizer (PFE) received FDA approval for its TUKYSA combination as front-line maintenance treatment for adults with HER2-positive advanced breast cancer. The approval covers TUKYSA with trastuzumab and pertuzumab after induction treatment for unresectable locally advanced or metastatic disease, providing a chemotherapy-free maintenance option.
In the Phase 3 HER2CLIMB-05 trial, median investigator-assessed progression-free survival—the time without cancer worsening or death—was 24.9 months versus 16.3 months with placebo, both alongside trastuzumab and pertuzumab. The primary analysis showed a 35.9% reduction in progression or death risk. Liver toxicity was more severe than TUKYSA's known safety profile. Serious adverse reactions occurred in 17% of TUKYSA recipients, including one fatal drug-induced liver injury. TUKYSA carries a boxed warning for severe and fatal liver toxicity, particularly after restarting treatment.
Astellas Pharma (TSE: 4503) will present 21 oncology abstracts at ESMO 2026, scheduled for October 23–27 in Madrid, Spain. Presentations include long-term follow-up of enfortumab vedotin with or without pembrolizumab in advanced bladder cancer, alongside subgroup analyses and bladder-preservation trials in progress. Zolbetuximab research covers CLDN18.2, a protein used to identify patients for treatment, and real-world use in gastric and gastroesophageal junction cancers.
The program also includes enzalutamide research in prostate cancer and ongoing investigational studies: Phase 3 setidegrasib trials in pancreatic and non-small cell lung cancers, a Phase 1 ASP5834 trial and a Phase 1b/2 ASP546C trial.
Pfizer (NYSE: PFE) declared a fourth-quarter 2026 cash dividend of $0.43 per common share, payable December 7, 2026.
Shareholders of record at the close of business on November 6, 2026 qualify for the payment. Pfizer said its capital allocation strategy includes maintaining the dividend and growing it over the longer term.
Pfizer (PFE) presented two Phase 3 trials showing LITFULO improved facial and total body repigmentation versus placebo in nonsegmental vitiligo. At Week 52, at least 75% improvement in facial pigmentation occurred in 21.86% versus 2.40% with 100 mg in TRANQUILLO 2 and 12.47% versus 2.48% with 50 mg in TRANQUILLO. At least 50% improvement in total body pigmentation occurred in 13.02% versus 2.40% and 8.98% versus 1.98%, respectively.
Improvements appeared by Week 24 and increased through Week 52; patient-reported disease severity also improved. No new safety signals emerged, although adverse events occurred in 67.7% versus 62.0% in TRANQUILLO 2 and 81.0% versus 77.1% in TRANQUILLO. The trials evaluated 2,174 patients. Pfizer intends to submit the data globally, including to the FDA and EMA, for a potential adult vitiligo indication.